What kind of drug does Sunitinib (Sutent) belong to and analysis of its main clinical uses

Sunitinib (Sunitinib, trade name: Sutent) is a small molecule targeted drug that is a multi-target tyrosine kinase inhibitor (TKI). It inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-KIT, FLT3 And other signaling pathways, thereby blocking the proliferation and angiogenesis of tumor cells, and achieving the purpose of inhibiting tumor growth and spread. Unlike traditional chemotherapy, sunitinib does not directly kill rapidly dividing cells, but works by "cutting off tumor supply pathways", so the side effect spectrum is also different from traditional drugs.

Clinically, sunitinib is widely used to treat a variety of malignant tumors. The earliest indication is advanced renal cell carcinoma (RCC), and it is still one of the important first-line treatment options for this disease. In addition, sunitinib is also approved for the treatment of gastrointestinal stromal tumors (GIST), especially in patients who have failed or are intolerant to imatinib. In recent years, it has also been used in the treatment of pancreatic neuroendocrine tumors (pNET), providing new and effective treatment options for patients with this type of rare tumors.

Sunitinib has clear efficacy advantages in clinical use. For example, in patients with advanced renal cancer, studies have shown that sunitinib can significantly prolong progression-free survival (PFS) and overall survival (OS), and improve tumor response rates in some patients. In patients with gastrointestinal stromal tumors, the application of sunitinib also significantly delayed disease progression and became the standard drug after imatinib resistance. For pancreatic neuroendocrine tumors, sunitinib can not only effectively control the disease, but also improve the patient's quality of life.

Generally speaking, sunitinib is a multi-target targeted drug, and its clinical application is mainly concentrated in three major areas: renal cancer, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. Because of its unique mechanism of action and its ability to effectively block the blood supply and signaling pathways of tumors, it occupies an important position in the treatment of multiple tumors. Although its side effects require monitoring and management, the emergence of sunitinib has greatly improved the treatment prospects for some patients with advanced malignant tumors, giving patients more hope for survival.

Reference materials:https://www.drugs.com/